Results 101 to 110 of about 31,394 (214)

Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 2, August 2026.
ABSTRACT The 3‐hydroxy‐3‐methyl‐glutaryl‐coenzyme A reductase inhibitor rosuvastatin is a substrate of breast cancer resistance protein (BCRP). BCRP inhibition increases rosuvastatin plasma concentrations and may result in concentration‐dependent muscle toxicity, at worst rhabdomyolysis.
Ronja Levomäki, Päivi Hirvensalo, Aleksi Tornio, Anne M. Filppula   +3 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interactions of Imlunestrant in Healthy Female Participants of Nonchildbearing Potential

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Imlunestrant is a next‐generation, oral, selective estrogen receptor degrader approved for treating adults with estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative, ESR1‐mutated advanced/metastatic breast cancer. Imlunestrant is metabolized partly by cytochrome P450 (CYP)3A4 oxidation and conjugation with glucuronic ...
Amita Datta‐Mannan, Elaine Shanks, Eunice Yuen, Vivian Rodriguez Cruz, Xuejing Aimee Wang, Stephen David Hall   +5 more
wiley   +1 more source

Effects of different doses of rosuvastatin on blood lipids and lipoproteins, endothelial function, and cerebral blood flow in patients with hyperlipidemia and cerebral ischemic stroke-complicated hypertension

КардиоСоматика, 2013
Objective: to study the dose-dependent effect of rosuvastatin on blood lipids and lipoproteins (LP), endothelial functional activity, coagulation, and safety parameters in patients with hyperlipidemia (HLP) and hypertension after cerebral ischemic stroke
M. G Bubnova, E. G Semenova, D. M Aronov, T. T Batysheva   +3 more
doaj  

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

Journal of Diabetes Investigation, Volume 17, Issue 8, Page 1367-1378, August 2026.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi, Jimin Jeon, Minyoul Baik, Joonsang Yoo, Jinkwon Kim   +4 more
wiley   +1 more source

Statin treatment: myths and reality

Кардиоваскулярная терапия и профилактика, 2008
Aim. To assess effectiveness and tolerability of rosuvastatin treatment, as a part of primary and secondary cardiovascular prevention, in patients with high and very high cardiovascular risk and dyslipidemia.Material and methods.
L. A. Malay, B. V. Sharykin, A. N. Miroshnichenko, V. V. Konurovsky, E. E. Kusnetsova, O. I. Vasina   +5 more
doaj  

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

New England Journal of Medicine, 2008
P. Ridker, E. Danielson, F. Fonseca, J. Genest, A. Gotto, J. Kastelein, W. Koenig, P. Libby, A. Lorenzatti, Jean G Macfadyen, B. Nordestgaard, J. Shepherd, J. Willerson, R. Glynn   +13 more
semanticscholar   +1 more source

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2010
Henri K Parson, Meredith A Bundy, Charlotte B Dublin, Amanda L Boyd, James F Paulson, Aaron I VinikLeonard R. Strelitz Diabetes Center, Department of Internal Medicine Eastern Virginia Medical School, Norfolk, Virginia, USAAbstract: Rosuvastatin is known
Parson H
doaj   +2 more sources

Transfer of rosuvastatin into breast milk: liquid chromatography–mass spectrometry methodology and clinical recommendations

Drug Design, Development and Therapy, 2018
Ei Mon Phyo Lwin,1 Catherine Leggett,2 Usha Ritchie,2 Cobus Gerber,1 Yunmei Song,1 William Hague,3,4 Sean Turner,2 Richard Upton,1 Sanjay Garg11School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5000, Australia; 2SA ...
Lwin EMP, Leggett C, Ritchie U, Gerber C, Song Y, Hague W, Turner S, Upton R, Garg S   +8 more
doaj  

The Effect of Rosuvastatin on a murine model of deep vein thrombosis

Thrombosis Update
Introduction: Rosuvastatin reduces C-reactive protein and cardiovascular mortality. After deep vein thrombosis (DVT), elevated inflammatory markers persist.
Megan E. Barney, Shenghao Zhou, Anh Le-Cook, Naly Setthavongsack, Gabriel Nager, Jennifer M. Loftis, Randy L. Woltjer, Monica Hinds, Khanh P. Nguyen   +8 more
doaj   +1 more source

Effect of epigallocatechin-3-gallate, major ingredient of green tea, on the pharmacokinetics of rosuvastatin in healthy volunteers

Drug Design, Development and Therapy, 2017
Tae-Eun Kim,1 Na Ha,2 Yunjeong Kim,2 Hyunsook Kim,1 Jae Wook Lee,3 Ji-Young Jeon,2 Min-Gul Kim2,4 1Department of Clinical Pharmacology, Konkuk University Medical Center, Seoul, 2Center for Clinical Pharmacology, Biomedical Research Institute, Chonbuk ...
Kim TE, Ha N, Kim Y, Kim H, Lee JW, Jeon JY, Kim MG   +6 more
doaj